Last reviewed · How we verify
Vaxigrip Tetra Sanofi Pasteur Europe
Vaxigrip Tetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.
Vaxigrip Tetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children ≥6 months of age.
At a glance
| Generic name | Vaxigrip Tetra Sanofi Pasteur Europe |
|---|---|
| Sponsor | Aarhus University Hospital |
| Drug class | Inactivated influenza vaccine (quadrivalent) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus particles representing four circulating influenza strains (two A subtypes and two B lineages). Upon intramuscular injection, these antigens trigger both humoral and cellular immune responses, leading to the production of strain-specific antibodies and T-cell immunity that protect against infection with matching influenza viruses.
Approved indications
- Seasonal influenza prevention in adults and children ≥6 months of age
Common side effects
- Injection site pain, redness, or swelling
- Myalgia (muscle pain)
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE (PHASE4)
- INfluenza VaccInation To Mitigate typE 1 Diabetes (PHASE4)
- Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaxigrip Tetra Sanofi Pasteur Europe CI brief — competitive landscape report
- Vaxigrip Tetra Sanofi Pasteur Europe updates RSS · CI watch RSS
- Aarhus University Hospital portfolio CI